LifeMD (NASDAQ:LFMD) Upgraded to Hold at Wall Street Zen

LifeMD (NASDAQ:LFMD) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

A number of other brokerages have also recently weighed in on LFMD. B. Riley Financial reduced their price target on shares of LifeMD from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. Loop Capital set a $10.00 price objective on LifeMD in a research note on Thursday. Mizuho reduced their target price on LifeMD from $8.00 to $6.00 and set a “neutral” rating on the stock in a report on Wednesday, November 19th. BTIG Research reissued a “buy” rating and issued a $10.00 target price on shares of LifeMD in a research note on Tuesday. Finally, HC Wainwright increased their price target on LifeMD from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Wednesday. Six research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.86.

LifeMD Price Performance

Shares of NASDAQ:LFMD opened at $3.98 on Friday. The firm’s 50 day simple moving average is $3.33 and its 200 day simple moving average is $4.54. LifeMD has a fifty-two week low of $2.56 and a fifty-two week high of $15.84. The company has a market capitalization of $190.92 million, a price-to-earnings ratio of 15.31 and a beta of 1.92.

LifeMD (NASDAQ:LFMD) last issued its quarterly earnings data on Monday, March 9th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.03). LifeMD had a net margin of 6.58% and a negative return on equity of 83.93%. The firm had revenue of $46.87 million for the quarter, compared to analyst estimates of $48.57 million. Equities research analysts expect that LifeMD will post -0.56 earnings per share for the current year.

Institutional Investors Weigh In On LifeMD

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in LifeMD by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,647 shares of the company’s stock valued at $270,000 after acquiring an additional 2,235 shares in the last quarter. Campbell & CO Investment Adviser LLC bought a new position in LifeMD during the 2nd quarter worth about $359,000. Geode Capital Management LLC raised its stake in shares of LifeMD by 7.9% in the 2nd quarter. Geode Capital Management LLC now owns 925,173 shares of the company’s stock valued at $12,603,000 after purchasing an additional 67,440 shares during the period. Calamos Advisors LLC acquired a new stake in shares of LifeMD in the 2nd quarter valued at about $543,000. Finally, SG Americas Securities LLC lifted its holdings in shares of LifeMD by 97.6% in the second quarter. SG Americas Securities LLC now owns 21,948 shares of the company’s stock valued at $299,000 after purchasing an additional 10,843 shares in the last quarter. 35.52% of the stock is currently owned by institutional investors and hedge funds.

About LifeMD

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.